CHOICE — what influences EGFR‑TKI treatment decisions for Chinese patients with stage IV non‑small cell lung cancer

A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)

This project uses surveys to see what features of first‑line EGFR‑TKI treatments patients and doctors in China prefer when choosing care for people with stage IV non‑small cell lung cancer.

Quick facts

• Study type: Observational
• Enrollment: 590 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: AstraZeneca (Industry-sponsored)
• Locations: 1 site (Chengdu)
• Trial ID: NCT07413757 on ClinicalTrials.gov

What this trial studies

This non‑interventional, cross‑sectional study uses a survey including a discrete choice experiment (DCE) to capture treatment preferences from physicians and patients with experience of first‑line EGFR‑TKI therapy for stage IV NSCLC. Stage 1 focuses on qualitative work and questionnaire development, including identification of key attributes and pilot testing. Stage 2 implements the finalized quantitative survey and analyzes responses to identify which treatment attributes and patient factors drive decision‑making. Data are collected from consenting adult patients and eligible oncology physicians at the designated research site.

Who should consider this trial

Good fit: Adults (age ≥18) with stage IV non‑small cell lung cancer who are currently or previously treated with first‑line EGFR‑TKI, can give informed consent, and can communicate without cognitive or language barriers are ideal candidates.

Not a fit: Patients who have never received first‑line EGFR‑TKI treatment, have significant cognitive or communication impairments, or whose care cannot be linked to the study site are unlikely to receive benefit from participating.

Why it matters

Potential benefit: If successful, findings could help clinicians and patients choose EGFR‑TKI treatments that better match patient priorities and improve shared decision‑making.

How similar studies have performed: Discrete choice experiments and preference surveys have been used successfully in oncology to reveal patient and physician priorities, though applying a DCE specifically to Chinese stage IV NSCLC EGFR‑TKI choices is a more specialized application.

Eligibility criteria

Inclusion Criteria:

The following inclusion criteria must be met in order to be enrolled in the stage 1:

Patient:

* Provide informed consent
* 18 years or older
* Diagnosed with stage IV NSCLC
* Currently receiving or previously received 1L EGFR-TKI treatment
* Without communication barrier
* Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter

Physician:

* Provide informed consent
* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
* Holding the title of associate chief physician or higher

The following inclusion criteria must be met in order to be enrolled in the stage 2:

Patient:

* Provide informed consent
* 18 years or older
* Diagnosed with stage IV NSCLC
* Currently receiving or previously received 1L EGFR-TKI treatment
* Without communication barrier
* Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter

Physician:

* Provide informed consent
* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
* Holding the title of attending physician or higher

Exclusion Criteria:

Not applicable.

Where this trial is running

Chengdu

• Research Site — Chengdu, China (Recruiting)

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center

Conditions Non-Small Cell Lung Cancer; NSCLC; patients and physicians; survey; EGFR-TKI; patient preference; physician preference